Testing Temozolomide and M1774 Combination
Phase 1/2
58
about 3.4 years
18+
23 sites in CA, CT, IL +6
What this study is about
This trial is testing the safety and effectiveness of a combination treatment with temozolomide and M1774 in patients with advanced cancer. The goal is to determine the best dose of this combination and how well it works in treating different types of cancer that has spread to other parts of the body.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Temozolomide
- 2.Take Tuvusertib
- 3.Undergo Biopsy Procedure
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
temozolomide
injection, intravenous
Primary: Dose limiting toxicity and the maximum tolerated dose
Secondary: Objective response rate (ORR), Overall survival (OS), Progression free survival (PFS), Rate of >= grade 3 adverse events (AE)
biopsy, diagnostic, imaging
Oncology